Natural compound shows promise against C. difficile while largely sparing healthy gut bacteria
The pathogen Clostridioides difficile (C. difficile) is naturally present in the intestines of many people. When present in small numbers, it usually causes no symptoms. Treatment with broad-spectrum antibiotics can severely disrupt the balance of the healthy gut microbiome, allowing the bacterium to multiply unchecked. The result is acute intestinal inflammation, which can also become chronic.…
A research team from Hannover Medical School, Saarland University Hospital, and the Helmholtz Institute for Pharmaceutical Research Saarland has discovered that the natural compound argyrin B is highly effective against the pathogen Clostridioides difficile (C. difficile) while largely sparing the beneficial gut microbiome. This compound, previously identified in soil-dwelling myxobacteria, showed significant reduction in bacterial load in laboratory experiments and a mouse model of C. difficile infection.
Importantly, argyrin B had minimal effects on the beneficial microorganisms in the digestive tract. The compound demonstrated minimal absorption into the bloodstream after oral dosing in mice, remaining primarily in the large intestine. This suggests that argyrin B could be a well-tolerated therapeutic approach against C. difficile, potentially reducing the need for fecal microbiota transfer, a complex and unpleasant procedure.
Further studies are needed to determine the optimal dosage and test the compound's efficacy against recurrent infections.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
